Jove
Visualize
Contact Us

Related Experiment Videos

Technology evaluation: colostrinin, ReGen.

Marcus Rattray1

  • 1King's College London, The Wolfson Centre for Age-Related Diseases, London, UK. marcus.rattray@kcl.ac.uk

Current Opinion in Molecular Therapeutics
|March 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study.

The pharmacogenomics journal·2026
Same author

An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis.

Frontiers in genetics·2021
Same author

Patient Perspectives on Factors Affecting Direct Oral Anticoagulant Use for Stroke Prevention in Atrial Fibrillation.

Patient preference and adherence·2021
Same author

Endoplasmic Reticulum Stress Signalling Induces Casein Kinase 1-Dependent Formation of Cytosolic TDP-43 Inclusions in Motor Neuron-Like Cells.

Neurochemical research·2019
Same author

Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.

ACS medicinal chemistry letters·2018
Same author

Erratum.

Advances in neurobiology·2017
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

ReGen Therapeutics is investigating Colostrinin, a natural polypeptide complex, as a potential Alzheimer's disease treatment. This promising Alzheimer's drug candidate is currently in phase II clinical trials.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited effective treatments.
  • Developing novel therapeutic agents for AD remains a significant unmet medical need.

Purpose of the Study:

  • To evaluate the safety and efficacy of Colostrinin for the potential treatment of Alzheimer's disease.
  • To advance Colostrinin through clinical development for AD therapy.

Main Methods:

  • Colostrinin, a polypeptide complex derived from ovine colostrum, is the investigational compound.
  • The compound is currently being assessed in phase II clinical trials.

Main Results:

  • Preliminary data on Colostrinin's efficacy and safety in AD patients are anticipated from ongoing trials.

Related Experiment Videos

  • Phase II trials are designed to provide crucial information on therapeutic potential.

    • Conclusions:

    • Colostrinin represents a novel therapeutic approach for Alzheimer's disease, derived from a natural source.
    • Successful completion of phase II trials could pave the way for further development of Colostrinin as an AD treatment.